181 related articles for article (PubMed ID: 24466160)
1. Heterogeneity of tumor vasculature and antiangiogenic intervention: insights from MR angiography and DCE-MRI.
Zhu W; Kato Y; Artemov D
PLoS One; 2014; 9(1):e86583. PubMed ID: 24466160
[TBL] [Abstract][Full Text] [Related]
2. Water exchange-minimizing DCE-MRI protocol to detect changes in tumor vascular parameters: effect of bevacizumab/paclitaxel combination therapy.
Zhu W; Kato Y; Artemov D
MAGMA; 2014 Apr; 27(2):161-70. PubMed ID: 23807596
[TBL] [Abstract][Full Text] [Related]
3. Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts.
Lindholm EM; Kristian A; Nalwoga H; Krüger K; Nygård S; Akslen LA; Mælandsmo GM; Engebraaten O
Mol Oncol; 2012 Aug; 6(4):418-27. PubMed ID: 22521242
[TBL] [Abstract][Full Text] [Related]
4. Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts.
Zhou F; Hu J; Shao JH; Zou SB; Shen SL; Luo ZQ
J Cancer Res Clin Oncol; 2012 Nov; 138(11):1879-90. PubMed ID: 22736027
[TBL] [Abstract][Full Text] [Related]
5. Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors.
Hillman GG; Singh-Gupta V; Zhang H; Al-Bashir AK; Katkuri Y; Li M; Yunker CK; Patel AD; Abrams J; Haacke EM
Neoplasia; 2009 Sep; 11(9):910-20. PubMed ID: 19724685
[TBL] [Abstract][Full Text] [Related]
6. Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts.
Moestue SA; Huuse EM; Lindholm EM; Bofin A; Engebraaten O; Mælandsmo GM; Akslen LA; Gribbestad IS
J Magn Reson Imaging; 2013 Nov; 38(5):1043-53. PubMed ID: 23908122
[TBL] [Abstract][Full Text] [Related]
7. Integrin αvβ3-targeted dynamic contrast-enhanced magnetic resonance imaging using a gadolinium-loaded polyethylene gycol-dendrimer-cyclic RGD conjugate to evaluate tumor angiogenesis and to assess early antiangiogenic treatment response in a mouse xenograft tumor model.
Chen WT; Shih TT; Chen RC; Tu SY; Hsieh WY; Yang PC
Mol Imaging; 2012; 11(4):286-300. PubMed ID: 22954145
[TBL] [Abstract][Full Text] [Related]
8. Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis.
Mollard S; Ciccolini J; Imbs DC; El Cheikh R; Barbolosi D; Benzekry S
Oncotarget; 2017 Apr; 8(14):23087-23098. PubMed ID: 28416742
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive evaluation of antiangiogenic effect in a mouse tumor model by DCE-MRI with Gd-DTPA cystamine copolymers.
Wu X; Jeong EK; Emerson L; Hoffman J; Parker DL; Lu ZR
Mol Pharm; 2010 Feb; 7(1):41-8. PubMed ID: 19958031
[TBL] [Abstract][Full Text] [Related]
10. Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases.
Volk LD; Flister MJ; Chihade D; Desai N; Trieu V; Ran S
Neoplasia; 2011 Apr; 13(4):327-38. PubMed ID: 21472137
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage II or III HER2-negative breast cancer.
Mrózek E; Layman R; Ramaswamy B; Lustberg M; Vecchione A; Knopp MV; Shapiro CL
Clin Breast Cancer; 2014 Aug; 14(4):228-34. PubMed ID: 24703985
[TBL] [Abstract][Full Text] [Related]
12. [Effects of MRI-assayed microvascular permeability on the accumulation of vinorelbine in xenograft tumors].
Raatschen HJ; Fu Y; Rogut V; Simon GH; Sennino B; Wolf KJ; Brasch RC
Rofo; 2010 Feb; 182(2):133-9. PubMed ID: 19862658
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response.
Yopp AC; Schwartz LH; Kemeny N; Gultekin DH; Gönen M; Bamboat Z; Shia J; Haviland D; D'Angelica MI; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR
Ann Surg Oncol; 2011 Aug; 18(8):2192-9. PubMed ID: 21286939
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment.
Baker JHE; Kyle AH; Reinsberg SA; Moosvi F; Patrick HM; Cran J; Saatchi K; Häfeli U; Minchinton AI
Clin Exp Metastasis; 2018 Oct; 35(7):691-705. PubMed ID: 30196384
[TBL] [Abstract][Full Text] [Related]
15. Magnetic resonance imaging assays for dimethyl sulfoxide effect on cancer vasculature.
Cyran CC; Sennino B; Chaopathomkul B; Fu Y; Rogut V; Shames DM; Wendland MF; McDonald DM; Brasch RC
Invest Radiol; 2008 May; 43(5):298-305. PubMed ID: 18424950
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab improves the delivery and efficacy of paclitaxel.
Yanagisawa M; Yorozu K; Kurasawa M; Nakano K; Furugaki K; Yamashita Y; Mori K; Fujimoto-Ouchi K
Anticancer Drugs; 2010 Aug; 21(7):687-94. PubMed ID: 20559127
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experience.
Thukral A; Thomasson DM; Chow CK; Eulate R; Wedam SB; Gupta SN; Wise BJ; Steinberg SM; Liewehr DJ; Choyke PL; Swain SM
Radiology; 2007 Sep; 244(3):727-35. PubMed ID: 17709827
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a novel macromolecular cascade-polymer contrast medium for dynamic contrast-enhanced MRI monitoring of antiangiogenic bevacizumab therapy in a human melanoma model.
Cyran CC; Fu Y; Rogut V; Chaopathomkul B; Wendland MF; Shames DM; Brasch RC
Acad Radiol; 2013 Oct; 20(10):1256-63. PubMed ID: 24029057
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
Takahashi N; Haba A; Matsuno F; Seon BK
Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
[TBL] [Abstract][Full Text] [Related]
20. Dynamic Contrast-enhanced Magnetic Resonance Imaging for Patients with Breast Cancer Receiving First-line Bevacizumab and Paclitaxel.
Nakatsukasa K; Ouchi Y; Sakaguchi K; Goto M; Konishi E; Taguchi T
Anticancer Res; 2018 Sep; 38(9):5459-5463. PubMed ID: 30194203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
